EN DE
Watch Kamada for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Kamada (KMDA) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Kamada stock $7.02, price $7.23, that is 2.9% below the price, quality 63 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Israel · ISIN IL0010941198

K Kamada logo Broad data Nov 5, 2026

Kamada

KMDA · US
Fairly valued, in an uptrend

The stock costs about what our calculation considers fair.

Quality 63/100
Solidly profitable · 11.6% net margin (TTM)
Low debt
Generates free cash flow
3.5% dividend yield · Sustainable
Ranks above peers (14/15)
Broad data
Revenue last quarter +23% vs. a year ago.
Fair value $7.02 · Fairly valued
Mixed Growth (revenue 5y +6.3 %/yr in USD)
Moderate moat 50/100 · thin data
Insiders sold $1.7M (6M)
Watch Kamada for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$9.04 $3.58 Fair Value $7.02 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

60‑month range $3.58 – $9.04 · fair‑value band $4.70 – $9.62 · the $7.23 price screens above the $7.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 5, 2026.

Follow Kamada in your weekly email

Every Wednesday you see whether Kamada is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.

Show moreShow less

Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite.

The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers.

The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Stock analysis

Kamada (KMDA) currently trades at $7.23, while our model-based Fair Value estimate is $7.02, so the stock looks roughly fairly valued today (gap 3.0%).

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $8.33 per share, and 13 of the 26 models we run sit above the $7.23 price.

Bear case: the Asset-Based group reads lowest at $1.45, and 13 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: $4.70 (bear) to $9.62 (bull), the price of $7.23 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Kamada reported revenue of $180M in FY2025 versus $104M in FY2021, a compound +14.9%/yr. Reported net income was $20.2M in FY2025.

Key figures

Market cap $412M Small · P/E ratio 18.5 · P/S ratio 2.15 · EPS (TTM) $0.3900 · Dividend yield 3.5% · Net margin 11.6% · Return on equity 8.4% · Return on assets (EBIT) 3.3% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 20% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −3%, KMDA screens cheaper than that median.

Fair Value models

Bear $4.70 Fair Value $7.02 Bull $9.62
Price $7.23 · Downside -2.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.1197 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $4.69 $7.32 $11.59 79
Growth DCF $4.65 $7.02 $10.71 78
Owner Earnings $2.77 $4.00 $6.00 76
All 26 models by family
DCF Models
FCF DCF $4.69 $7.32 $11.59 79
Owner Earnings $2.77 $4.00 $6.00 76
5Y Revenue Exit $4.99 $8.01 $12.12 72
5Y EBITDA Exit $6.96 $12.06 $18.49 74
5Y P/E Exit $5.79 $9.67 $14.09 70
10Y Revenue Exit $4.71 $7.47 $11.71 66
10Y EBITDA Exit $6.10 $10.32 $16.81 67
10Y P/E Exit $5.35 $8.64 $13.29 63
Earnings-Based
Graham-Dodd $2.38 $10.85 $14.89 64
Lynch FV $2.84 $4.06 $5.28 61
PEG = 1.0 $2.84 $4.06 $5.28 57
EPV $4.60 $5.13 $5.59 74
Dividend Discount
Gordon GGM $1.85 $3.59 $5.30 67
DDM Multi-Stage $1.85 $3.15 $3.80 67
Multiples
P/E Multiple $5.77 $7.70 $9.62 63
P/S Multiple $4.46 $5.95 $7.44 58
P/B Multiple $5.74 $7.66 $9.57 55
EV/EBIT $6.90 $8.84 $10.77 66
EV/EBITDA $8.82 $11.39 $13.96 67
EV/Revenue $5.24 $7.02 $8.79 54
Asset-Based
NCAV (Graham) $0.9500 $1.45 $1.81 54
Growth DCF
Growth DCF $4.65 $7.02 $10.71 78
Rev-Margin DCF $4.99 $7.93 $11.71 72
Economic Profit
Residual Income $3.76 $3.98 $4.37 76
ROIC Compounder $4.60 $5.59 $6.86 72
Growth Earnings
Growth-Adj P/E $4.70 $6.72 $8.74 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 63/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 39
How much profit the company makes from its sales and capital
Quality Growth 65
Are margins and returns getting better?
Cashflow 52
Do the profits arrive as real cash?
Financial strength 93
Debt, balance sheet and risk of trouble
Investment 58
Does it invest with discipline instead of growing at any price?
Low Volatility 77
How calm the share price moves, does not count
Price momentum 40
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 36
Distance to the 52-week high, does not count
New shares 73
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $1.7M and none bought.

  • SaleDavid TsurDirector2× since Sep 7, 2026: 200,000 shares, avg. $8.25$1.7MSep 14, 2026

Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 77/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+12.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
Start year 2020 (pandemic). Over 10 years: +9.9% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.3%
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+19.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+16.4%
Dividend (yield on the price)3.5%
Per share before 2010divided by the spin-off factor 1.019
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 15%
2025 sits 71% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +8.4% a year for the price.

Watch KMDA, get fair value alerts →

Compare Kamada with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 14/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 63 · Above median
Fair Value upside −2.9% · Above median
Profitability
Return on equity (12 months) 8.4% · Above median
Return on assets 5.3% · Above median
Net margin (12 months) 11.6% · Above median
Operating margin (12 months) 17.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) 22.7% · Top 25%
Dividend yield (12 months) 3.5% · Top 25%
Balance sheet
Debt / equity 0.05× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 18.5× · Cheaper than median
P/B 1.53× · Cheaper than median
P/S (12 months) 2.15× · Cheaper than median
Price / free cash flow (fiscal year) 24.3× · Pricier than median
EV/EBITDA 8.4× · Cheaper than median
PEG 0.61× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)29 · sector 15
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)34 · sector 29
HEALTH (low debt)98 · sector 96
DIVIDEND (yield)69 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $111.63 +41% vs KMDA
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs KMDA
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs KMDA
Haleon plc HLN $9.14 $8.61 −6% vs KMDA
Merck KGaA MRK €148.75 €109.18 −27% vs KMDA
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs KMDA
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs KMDA
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs KMDA
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs KMDA
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs KMDA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Kamada: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Kamada Fair Value". https://www.fairvalue-calculator.com/stock/KMDA

Frequently asked questions

Is Kamada (KMDA) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $7.02 versus a price of $7.23, about 3% lower (fairly valued).
What is the fair value of KMDA?
Our model-based fair value for Kamada is $7.02 (as of Nov 5, 2026), built from audited fundamentals. The current price: $7.23.
What is the quality score of KMDA?
Kamada has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kamada (KMDA)?
Our model-based price target is the fair value of $7.02 (as of Nov 5, 2026) from 26 valuation models. Cautious scenario $4.70, optimistic scenario $9.62. It is a calculation from audited fundamentals, not an analyst target.
What is the Kamada stock forecast for 2026?
Our models put fair value at $7.02, about 3% lower versus a price of $7.23 (fairly valued). Cautious scenario $4.70, optimistic scenario $9.62. The calculation is refreshed regularly with new filings.
What is the revenue of Kamada (KMDA)?
Kamada reported trailing-twelve-month revenue of about $192M (latest available figure, as of Nov 5, 2026).
Does Kamada pay a dividend?
Kamada currently shows a dividend yield of 3.46% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Kamada (KMDA) and when is the ex-dividend date?
Kamada pays a dividend of $0.25 per share a year, a dividend yield of 3.5%. The last ex-dividend date was Aug 27, 2026. The payout ratio is 64.1% of earnings. Free cash flow covers the dividend 1.17 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Kamada (KMDA)?
For today's price to be fair in a discounted-cash-flow model, Kamada would have to grow free cash flow by +11.0 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.3 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of KMDA use?
Our models discount Kamada at 9.8 %: a base by market capitalisation (small), damped by beta 0.13, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Kamada that is +11.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has Kamada (KMDA) delivered so far?
Over the past 5 years revenue at Kamada grew +6.3 % a year. The price currently implies free-cash-flow growth of +11.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Kamada (KMDA) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Kamada (+11.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Kamada (KMDA)?
The free-cash-flow yield on the price is 4.05 %: that much free cash flow Kamada produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Kamada (KMDA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kamada it is $7.02 per share (as of Nov 5, 2026), against a price of $7.23. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Kamada stock overvalued or undervalued in 2026?
As of Nov 5, 2026, KMDA trades above its calculated fair value: price $7.23, fair value $7.02, a gap of about −3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KMDA?
No. The price is what the market pays today ($7.23); the fair value is what the company's own numbers justify ($7.02). For Kamada the two are $0.2100 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kamada worth?
The market values Kamada at about $412M (market capitalisation, as of Nov 5, 2026). Per share that is $7.23; our models calculate a fair value of $7.02 per share.
What do the bullish and bearish scenarios say about KMDA?
Our models span a range for Kamada: cautious scenario $4.70, base $7.02, optimistic $9.62 per share (as of Nov 5, 2026, price $7.23). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of KMDA?
Kamada trades at a price-to-earnings ratio of 18.5 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $7.02 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2017 to 2025), reported earnings: 20.4. Other multiples: PEG 0.6, P/B 1.5, P/S 2.1, EV/EBITDA 8.4.
What is the PEG ratio of KMDA?
The PEG ratio of Kamada is 0.61 (P/E divided by earnings growth, as of Nov 5, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Kamada (KMDA)?
Balance-sheet figures for Kamada (as of Nov 5, 2026): return on equity 8.4%, debt of 0.05 per unit of equity. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is KMDA from its 52-week high?
Kamada trades at $7.23, about 20% below its 52-week high of $9.04 and 13% above the low of $6.43 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $7.02 is for.
Which stocks are comparable to Kamada?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kamada stock attractive at the current price?
The data as of Nov 5, 2026: price $7.23, calculated fair value $7.02 (−3%), Quality Score 63/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KMDA calculated?
We run Kamada through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $7.02 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Kamada itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kamada (KMDA)?
The closing price on Nov 6, 2026 was $7.23. Our model-based fair value is $7.02, about 3% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kamada right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($4.70 to $9.62) leaves room in how you read the outcome.

Key figures of Kamada

How large is the market capitalisation of Kamada (KMDA)?
The market capitalisation of Kamada is $412M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kamada (KMDA)?
The price-to-sales ratio of Kamada is 2.15 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Kamada (KMDA)?
Earnings per share at Kamada are $0.3900 (price ÷ EPS = P/E 18.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Kamada (KMDA)?
The dividend yield of Kamada is 3.5% (payout 64.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Kamada (KMDA)?
The net margin of Kamada is 11.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kamada (KMDA)?
The return on equity (ROE) of Kamada is 8.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kamada (KMDA)?
On an EBIT basis the return on assets of Kamada is 3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kamada (KMDA)?
The operating margin of Kamada is 17.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kamada (KMDA)?
Revenue at Kamada is growing +22.7% versus a year earlier (3y avg +11.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kamada (KMDA)?
Earnings per share at Kamada are growing +23.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Kamada (KMDA) hold?
Kamada holds more cash than debt, $63.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Kamada in the live analysis

One click puts Kamada on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.